371 related articles for article (PubMed ID: 36264349)
1. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
Gregg LP; Navaneethan SD
Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349
[TBL] [Abstract][Full Text] [Related]
2. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Morales J; Palmer BF
Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
[TBL] [Abstract][Full Text] [Related]
3. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
Butler J; Anker SD; Lund LH; Coats AJS; Filippatos G; Siddiqi TJ; Friede T; Fabien V; Kosiborod M; Metra M; Piña IL; Pinto F; Rossignol P; van der Meer P; Bahit C; Belohlavek J; Böhm M; Brugts JJ; Cleland JGF; Ezekowitz J; Bayes-Genis A; Gotsman I; Goudev A; Khintibidze I; Lindenfeld J; Mentz RJ; Merkely B; Montes EC; Mullens W; Nicolau JC; Parkhomenko A; Ponikowski P; Seferovic PM; Senni M; Shlyakhto E; Cohen-Solal A; Szecsödy P; Jensen K; Dorigotti F; Weir MR; Pitt B
Eur Heart J; 2022 Nov; 43(41):4362-4373. PubMed ID: 35900838
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.
Gruver J; Al-Makki A; Shepler B
J Pharm Pharm Sci; 2023; 26():11892. PubMed ID: 38173862
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
6. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
7. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
9. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
Weir MR; Bushinsky DA; Benton WW; Woods SD; Mayo MR; Arthur SP; Pitt B; Bakris GL
Am J Med; 2018 May; 131(5):555-564.e3. PubMed ID: 29180023
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Hyperkalemia in Heart Failure.
DeFilippis EM; Desai AS
Curr Heart Fail Rep; 2017 Aug; 14(4):266-274. PubMed ID: 28656517
[TBL] [Abstract][Full Text] [Related]
11. Management of RAASi-associated hyperkalemia in patients with cardiovascular disease.
Silva-Cardoso J; Brito D; Frazão JM; Ferreira A; Bettencourt P; Branco P; Fonseca C
Heart Fail Rev; 2021 Jul; 26(4):891-896. PubMed ID: 33599908
[TBL] [Abstract][Full Text] [Related]
12. Novel potassium binders to optimize RAASi therapy in heart failure: A systematic review and meta-analysis.
Paolillo S; Basile C; Dell'Aversana S; Esposito I; Chirico A; Colella A; Esposito G; Santo MD; Fierro MF; Carbone F; Marzano F; Amato C; Gargiulo P; Perrone Filardi P
Eur J Intern Med; 2024 Jan; 119():109-117. PubMed ID: 37648583
[TBL] [Abstract][Full Text] [Related]
13. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
[TBL] [Abstract][Full Text] [Related]
14. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
15. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
Athyros VG; Sachinidis AG; Zografou I; Simoulidou E; Piperidou A; Stavropoulos N; Karagiannis A
Curr Pharm Des; 2018; 24(46):5542-5547. PubMed ID: 30848186
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of new potassium binders on hyperkalemia management in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials.
Carvalho PEP; Veiga TMA; Lacerda H; Tofanelli MR; Gewehr DM; Nunes MCP; Simões E Silva AC
Clin Res Cardiol; 2023 Jul; 112(7):991-1002. PubMed ID: 37140823
[TBL] [Abstract][Full Text] [Related]
17. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
Rafique Z; Peacock WF; LoVecchio F; Levy PD
Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
[TBL] [Abstract][Full Text] [Related]
18. Management of Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor: Strategies to Maintain Chronic Kidney Disease Patients with Type II Diabetes on Therapy.
Mahmud HA; Palmer BF
Cardiorenal Med; 2024; 14(1):191-201. PubMed ID: 38513618
[TBL] [Abstract][Full Text] [Related]
19. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
[TBL] [Abstract][Full Text] [Related]
20. Combination Therapy Using Sodium Zirconium Cyclosilicate and a Mineralocorticoid Receptor Antagonist in Patients with Heart Failure and Hyperkalemia.
Imamura T; Oshima A; Narang N; Ushijima R; Ueno Y; Ueno H; Kinugawa K
Intern Med; 2021; 60(13):2093-2095. PubMed ID: 34193775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
